AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1479-5876

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment ; volume:12 ; number:1 ; day:31 ; month:7 ; year:2014 ; pages:1-9 ; date:12.2014
Journal of translational medicine ; 12, Heft 1 (31.7.2014), 1-9, 12.2014

Creator: Caputo, Emilia

Contributor: Miceli, Roberta
Motti, Maria Letizia
Taté, Rosarita
Fratangelo, Federica
Botti, Gerardo
Mozzillo, Nicola
Carriero, Maria Vincenza
Cavalcanti, Ernesta
Palmieri, Giuseppe
Ciliberto, Gennaro
Pirozzi, Giuseppe
Ascierto, Paolo Antonio
SpringerLink (Online service)

DOI: 10.1186/s12967-014-0216-z

URN: urn:nbn:de:1111-2016041450774

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Caputo, Emilia
Miceli, Roberta
Motti, Maria Letizia
Taté, Rosarita
Fratangelo, Federica
Botti, Gerardo
Mozzillo, Nicola
Carriero, Maria Vincenza
Cavalcanti, Ernesta
Palmieri, Giuseppe
Ciliberto, Gennaro
Pirozzi, Giuseppe
Ascierto, Paolo Antonio
SpringerLink (Online service)

Other Objects (12)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

B-Raf and the inhibitors: from bench to bedside

Hochschulschrift

Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

B-Raf and the inhibitors: from bench to bedside

Hochschulschrift

Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

B-Raf and the inhibitors: from bench to bedside

Hochschulschrift

Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

B-Raf and the inhibitors: from bench to bedside

Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

B-Raf and the inhibitors: from bench to bedside

Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

B-Raf and the inhibitors: from bench to bedside

Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

Related objects

Reset password